Abstract:Targeted delivery of antitumor drugs is especially important for tumor therapy. Cell-penetrating peptides (CPPs) have been shown to be very effective drug carriers for tumor therapy. However, most CPPs lack tumor cell specificity. Here, we identified a highly efficient CPP, CAT, from the newly identified buffalo-derived cathelicidin family, which exhibits a preferential binding capacity for multiple tumor cell lines and delivers carried drug molecules into cells. CAT showed an approximately threefold to sixfold higher translocation efficiency than some reported cell-penetrating antimicrobial peptides, including the well-known classical CPP TAT. Moreover, the delivery efficiency of CAT was greater in a variety of tested tumor cells than in normal cells, especially for the human hepatoma cell line SMMC-7721, for which delivery was 7 times more efficient than the normal human embryonic lung cell line MRC-5, according to fluorescent labeling experiment results. CAT was conjugated to the Momordica charantia-derived type-I ribosome-inactivating protein MAP 30, and the cytotoxicity of the MAP 30-CAT fusion protein in the tumor cell line SMMC-7721 was significantly enhanced compared with that of the unconjugated MAP 30. The IC50 value of MAP 30-CAT was approximately 83 times lower than the IC50 value of the original MAP 30. Interestingly, the IC50 value of MAP 30 alone for MRC-5 was approximately twofold higher than the value for SMMC-7721, showing a small difference. However, when MAP 30 was conjugated to CAT, the difference in IC50 values between the two cell lines was significantly increased by 38-fold. The results of the flow cytometric detection of apoptosis revealed that the increase in cytotoxicity after CAT conjugation was mainly caused by the increased induction of apoptosis by the fusion protein. These results suggest that CAT, as a novel tumor-homing CPP, has great potential in drug delivery applications in vivo and will be beneficial to the development of tumor therapeutics.

Cathepsin D inhibitors based on tasiamide B derivatives with cell membrane permeability

Design, synthesis, and bioactivities of tasiamide B derivatives as cathepsin D inhibitors.

Cyanobacterial peptides as a prototype for the design of cathepsin D inhibitors.

Design, Synthesis and Evaluation of 3-(2-aminoheterocycle)-4-benzyloxyphenylbenzamide Derivatives As BACE-1 Inhibitors

Design, Synthesis And Biological Evaluation Of Tasiamide Analogues As Tumor Inhibitors

Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction.

Novel CADD-based Peptidyl Vinyl Ester Derivatives As Potential Proteasome Inhibitors

Design, Synthesis, and Biological Evaluation of New Cathepsin B-Sensitive Camptothecin Nanoparticles Equipped with A Novel Multifuctional Linker

Disulfide Cross-Linked Micelles of Novel HDAC Inhibitor Thailandepsin A for the Treatment of Breast Cancer.

Interactions of a Low Molecular Weight Inhibitor from Streptomyces sp. MBR04 with Human Cathepsin D: Implications in Mechanism of Inactivation

Design of Acid-Activated Cell Penetrating Peptide for Delivery of Active Molecules into Cancer Cells.

Novel thiazolotriazole and triazolothiadiazine scaffolds as selective tumor associated carbonic anhydrase inhibitors endowed with cathepsin B inhibition

Synthesis and biological evaluation of selective pepstatin based trifluoromethylated inhibitors of Cathepsin D

Correction to "Structure-Based Design, Optimization, and Evaluation of Potent Stabilized Peptide Inhibitors Disrupting MTDH and SND1 Interaction".

Molecular Modeling and Biological Effects of Peptidomimetic Inhibitors of TACE Activity.

Cathepsin D as a potential therapeutic target to enhance anticancer drug-induced apoptosis via RNF183-mediated destabilization of Bcl-xL in cancer cells

Design and Synthesis of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-1,2,3,4-tetrahydroisoquinoline-3-carboxamides As Novel Hsp90 Inhibitors.

Screening and Characterization of a Novel High-Efficiency Tumor-Homing Cell-Penetrating Peptide from the Buffalo Cathelicidin Family.

A Novel Dithiocarbamate Analogue with Potentially Decreased ALDH Inhibition Has Copper-Dependent Proteasome-Inhibitory and Apoptosis-Inducing Activity in Human Breast Cancer Cells.

Targeting Cathepsin B for Cancer Therapies.

Achieving Cell Penetration with Distance-Matching Cysteine Cross-Linkers: a Facile Route to Cell-Permeable Peptide Dual Inhibitors of Mdm2/Mdmx